Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Prologis Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $37.53 (market cap $4.59B), while Prologis Inc trades at $129.33 (market cap $122.87B). The key difference: Prologis Inc is far larger — about 26.8× Definium Therapeutics Inc. Common Shares's market cap, and Prologis Inc pays a 3.31% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Prologis Inc for 102 Days on average.
| DFTX | PLD | |
|---|---|---|
Market Cap | $4.59B | $122.87B |
Volume | 2,103,937 | 4,222,957 |
Sector | Health | Real Estate |
52-Week High | $48.45 | $149.96 |
52-Week Low | $10.68 | $111.23 |
Typical Hold Time | 0 Days | 102 Days |
Enterprise Value | $3.55B | $157.61B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Prologis (PLD) trades at $129.18, up 1.48% today, with a bearish technical signal but strong fundamentals. The stock faces near-term resistance at $130, with support at $127. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $1.13 versus $0.747 expected. Revenue grew to $8.79B in 2025, and net income margin remains robust at 45.79%. The company benefits from strong warehouse demand driven by e-commerce and data centers, as highlighted in recent news.
Outlook is positive with a consensus price target of $155.15, implying 20% upside, supported by 59.5% analyst buy ratings. Risks include rising debt-to-asset ratio (37.2% in 2025) and macroeconomic sensitivity. Institutional interest is strong, with QRG Capital increasing holdings by 11% in Q2 2026. The dividend yield of approximately 0.83% adds income appeal, but investors should monitor leverage and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
